Virtual Poster Session in Oncology From Madrid
Virtual Poster
Virtual Poster

Virtual Poster Session in Oncology From Madrid

Practical Application of Key Data Presented During the 2017 European Oncology Congress

Not a member of My prIME? Join now for instant access.

View CME-certified abstract presentations and downloadable slides covering the most up-to-date clinical trial data from the 2017 European Oncology Congress in Madrid.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

CME

CME

4.25 AMA PRA Category 1 Credits

Release Date

Release Date

Sep 18, 2017

Expiration Date

Sep 18, 2018

Gastrointestinal Cancer

Colin Weekes, MD

Abstract #380P A phase 1b study evaluating the safety and pharmacokinetics (PK) of regorafenib (REG) in combination with cetuximab (CTX) in patients with advanced solid tumors

Featured Expert: Colin Weekes, MD

Michael Geissler, MD, PhD

Abstract #475O mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer m(CRC): A randomized phase II VOLFI trial of the AIO (AIO-KRK0109)

Presented by: Michael Geissler, MD, PhD

Jordi Bruix, MD, PhD

Abstract #625PD Protein biomarkers as predictors of outcome with regorafenib (REG) in patients (pts) with hepatocellular carcinoma (HCC) in the RESORCE trial

Presented by: Jordi Bruix, MD, PhD

Jordi Bruix, MD, PhD

Abstract #705P Circulating miRNA biomarkers predicting regorafenib (REG) clinical benefit in patients with hepatocellular carcinoma (HCC) in the RESORCE trial

Presented by: Jordi Bruix, MD, PhD

Zev Wainberg, MD

Abstract #LBA28_PR KEYNOTE-059 update: Efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal (G/GEJ) cancer

Presented by: Zev Wainberg, MD

Richard Finn, MD

Abstract #LBA30 Analysis of serum biomarkers (BM) in patients (pts) from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC)

Presented by: Richard Finn, MD

Glioblastoma

Giuseppe Lombardi, MD

Abstract #LBA16 REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib activity in relapsed glioblastoma patients

Presented by: Giuseppe Lombardi, MD

Michael Lim, MD

Abstract #325O Nivolumab (nivo) in combination with radiotherapy (RT) ± temozolomide (TMZ): Updated safety results from CheckMate 143 in pts with methylated or unmethylated newly diagnosed glioblastoma (GBM)

Presented by: Michael Lim, MD

Martin van den Bent, MD

Abstract #327O Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized clinical trials in glioblastomal

Presented by: Martin van den Bent, MD

Gynecologic Cancer

Jonathan Ledermann, BSc, MD, FRCP

Abstract #LBA40_PR ARIEL3: A phase 3, randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (OC)

Presented by: Jonathan Ledermann, BSc, MD, FRCP

Eric Pujade-Lauraine, MD, PhD

Abstract #932PD Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: Phase III SOLO2 trial (ENGOT Ov-21)

Presented by: Eric Pujade-Lauraine, MD, PhD

Lung Cancer

Hossein Borghaei, DO

Abstract #LBA49 Updated results from KEYNOTE-021 cohort G: A randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC

Presented by: Hossein Borghaei, DO

David Spigel, MD

Abstract #1297O Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC)

Presented by: David Spigel, MD

Sai-Hong Ignatius Ou, MD, PhD

Abstract #1345P Intracranial efficacy of brigatinib (BRG) in patients (Pts) with crizotinib (CRZ)-rRefractory anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC) and baseline CNS metastases

Presented by: Sai-Hong Ignatius Ou, MD, PhD

Suresh Ramalingam, MD

Abstract #LBA2_PR Osimertinib vs SoC EGFR-TKI as first-line therapy in patients with EGFRm advanced NSCLC (FLAURA)

Presented by: Suresh Ramalingam, MD

Luis Paz-Ares, MD

Abstract #LBA1_PR PACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy (CRT) in patients with stage III, locally advanced, unresectable NSCLC

Presented by: Luis Paz-Ares, MD

Neuroendocrine Tumors

Janice Mehnert, MD

Abstract #427O Pembrolizumab for patients with PD-L1–positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study

Presented by: Janice Mehnert, MD

Jaume Capdevila, MD, PhD

Abstract #430O Different RNA expression profile defines prognosis in grade 1/2 neuroendocrine neoplasms of small intestine origin: The GETNE-NETSEQ study

Presented by: Jaume Capdevila, MD, PhD

Dieter Hörsch, MD, PhD

Abstract #440PD Efficacy and safety of telotristat ethyl in patients with carcinoid syndrome inadequately controlled by somatostatin analogs: Analysis of the completed TELESTAR extension

Presented by: Dieter Hörsch, MD, PhD

Jaroslaw Ćwikla, MD, PhD

Abstract #451P Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide autogel/depot 120mg in the CLARINET open-label extension

Presented by: Jaroslaw Ćwikla, MD, PhD

Faculty

  • Martin van den Bent, MDErasmus MC Kanker Instituut
    Rotterdam, the Netherlands
  • Hossein Borghaei, DOFox Chase Cancer Center
    Philadelphia, Pennsylvania, United States
  • Jordi Bruix, MD, PhDUniversity of Barcelona
    Barcelona, Spain
  • Jaume Capdevila, MD, PhDVall d’Hebron University Hospital
    Barcelona, Spain
  • Jaroslaw Ćwikla, MD, PhDUniversity of Warmia and Mazury
    Olsztyn, Poland
  • Richard Finn, MDUCLA Medical Center
    Santa Monica, California, United States
  • Michael Geissler, MD, PhDKlinikum Esslingen
    Esslingen, Germany
  • Dieter Hörsch, MD, PhDCenter for Neuroendocrine Tumors Bad Berka
    Bad Berka, Germany
  • Jonathan Ledermann, BSc, MD, FRCPUCL Cancer Institute, University College London
    London, United Kingdom
  • Michael Lim, MDJohns Hopkins Medicine
    Baltimore, Maryland, United States
  • Giuseppe Lombardi, MDIstituto Oncologico Veneto
    Padova, Italy
  • Janice Mehnert, MDRutgers Cancer Institute of New Jersey
    New Brunswick, New Jersey, United States
  • Sai-Hong Ignatius Ou, MD, PhDUC Irvine Medical Center
    Orange, California, United States
  • Luis Paz-Ares, MDHospital Universitario Virgen del Rocío
    Seville, Spain
  • Eric Pujade-Lauraine, MD, PhDCentre Hospitalier Universitaire Hôtel-Dieu
    Paris, France
  • Suresh Ramalingam, MDWinship Cancer Institute
    Emory University
    Atlanta, Georgia, United States
  • David Spigel, MDSarah Cannon Research Institute
    Nashville, Tennessee, United States
  • Zev Wainberg, MDUCLA Medical Center
    Santa Monica, California, United States
  • Colin Weekes, MDMassachusetts General Hospital
    Boston, Massachusetts, United States

This activity is specifically designed to meet the needs of medical, surgical, and radiation oncologists, hematologists, and other healthcare professionals involved in the treatment of patients with cancer.

After successful completion of this educational activity, participants should be able to:

  • Evaluate developing clinical trial data for new and emerging agents and compare with established therapy options
  • Identify patients who may benefit from referral to a clinical trial

This educational activity is supported by grants from Bayer HealthCare Pharmaceuticals, Inc.; Clovis Oncology; Ipsen; Merck and Co, Inc.; and Takeda Oncology.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Virtual Poster Session in Oncology From Madrid - prIME Oncology

prIME Oncology designates this enduring activity for a maximum of 4.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Each module may provide the following credits:

  • Gastrointestinal Cancer: 1.25
  • Glioblastoma Cancer: 0.5
  • Gynecologic Cancer: 0.5
  • Lung Cancer: 1.25
  • Neuroendocrine Tumors: 0.75

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

A link to the posttest is available on the video player pages.

In order to receive credit, participants must successfully complete the online posttests with 75% or higher.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Dr van den Bent has disclosed that he has received consulting fees from AbbVie, Celgene, and Daiichi Sankyo. He has also received fees for speaking and teaching from MSD. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Borghaei has disclosed that he has received consulting fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Genentech, Genmab, Lilly, Novartis Oncology, and Pfizer. He has also performed independent contract work for Celgene Corporation, Merck, and Millennium Pharmaceuticals. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Bruix has disclosed that he has received consulting fees from Abbott, Arqule, Bayer, Bristol-Myers Squibb, BTG, Daiichi Sankyo, GlaxoSmithKline, Kowa, Lilly, Novartis, and Roche. He has also received honoraria for promotional speaker’s bureaus and has received fees for speaking and teaching from Bayer, BTG, and Sirtex. Furthermore, he has worked as an independent contractor for Arqule, Bayer, and Daiichi Sankyo. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Capedevila has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Ćwikla has disclosed that he has performed independent contracting for Ipsen. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Finn has disclosed that he has received consulting fees from Bayer HealthCare Pharmaceuticals, Inc., Bristol-Myers Squibb, Eisai, Novartis Oncology, and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Geissler has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Hörsch has disclosed that he has received consulting fees from Ipsen. He has received honoraria for promotional speaker’s bureaus and he is a member of an advisory committee or review panel for Ipsen and Lexicon Pharmaceuticals. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Ledermann has disclosed that he has received consulting fees from AstraZeneca, Clovis Oncology, Pfizer, and Roche. He has received honoraria for promotional speaker’s bureaus from AstraZeneca, Clovis Oncology, and Pfizer. He is a member of the AstraZeneca Steering Group. He also received an academic research grant from AstraZeneca. Furthermore, he has received fees for speaking and teaching from He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Lim has disclosed that he has received consulting fees from Bristol-Myers Squibb, Baxter, Merck, and Stryker. He has a board membership with Boston Biomedical and Oncorus. He has also received research from Accuray, Agenus, and Bristol-Myers Squibb. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Lombardi has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Mehnert has disclosed that she has received consulting fees from Merck. She has performed contracted research with grants going to her institution for Amgen, AstraZeneca, EMD Serono, Immunocore, Incyte, Macrogenics, and Merck. She has also received fees for speaking and teaching from Pfizer. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Ou has disclosed that he has received consulting fees from AstraZeneca, Novartis, Pfizer, Roche, and Takeda/Ariad. He also disclosed receipt of honoraria for participation in promotional speaker’s bureaus from AstraZeneca, Genentech, and Takeda/Ariad. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Paz-Ares has disclosed that he has received honoraria for promotional speaker’s bureaus from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Lilly, MSD, Novartis Oncology, Pfizer, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Pujade-Lauraine has disclosed that he is a member of advisory committees or review panels for AstraZeneca, Clovis, Pfizer, Roche, and Tesaro. He has also received fees for speaking and teaching from AstraZeneca and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Ramalingam has disclosed that he has received consulting fees from Abbvie, Amgen, AstraZeneca, BMS, Genentech, Lilly, Merck, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Spigel has disclosed that he has received consulting fees on behalf of his institution from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Clovis Oncology, Genentech/Roche, Lilly, Novartis, and Pfizer. He also disclosed receipt of research funding to his institution from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Clovis Oncology, Daiichi Sankyo, Genentech/Roche, Lilly, Merck, Novartis, Oncogenex, OncoMed, Peregrine Pharmaceuticals, Pfizer, and Verastem. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Wainburg has disclosed that he has received consulting fees from Array, Five Prime, Genentech, and Sirtex. He also disclosed receipt of honoraria for participation in a promotional speaker’s bureau from Genentech. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Weekes has disclosed that he has received honoraria for promotional speaker’s bureau from Lilly. He is a member of an advisory board committee or review panel for Merrimack Pharmaceuticals, Inc. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Briana Betz, PhD (clinical content reviewer/planner) – no relevant financial relationships
  • Jessica Mastrodomenico, MPH (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.